- Home
- VIGL vs OCCI Comparison
VIGL vs OCCI Comparison
Compare VIGL & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- OCCI
- Stock Information
- Founded
- VIGL 2020
- OCCI N/A
- Country
- VIGL United States
- OCCI United States
- Employees
- VIGL N/A
- OCCI N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- VIGL Health Care
- OCCI Finance
- Exchange
- VIGL Nasdaq
- OCCI Nasdaq
- Market Cap
- VIGL 141.5M
- OCCI 117.5M
- IPO Year
- VIGL 2022
- OCCI N/A
- Fundamental
- Price
- VIGL $3.00
- OCCI $7.07
- Analyst Decision
- VIGL Buy
- OCCI
- Analyst Count
- VIGL 5
- OCCI 0
- Target Price
- VIGL $16.80
- OCCI N/A
- AVG Volume (30 Days)
- VIGL 51.3K
- OCCI 115.8K
- Earning Date
- VIGL 11-07-2024
- OCCI 12-11-2023
- Dividend Yield
- VIGL N/A
- OCCI 24.32%
- EPS Growth
- VIGL N/A
- OCCI N/A
- EPS
- VIGL N/A
- OCCI N/A
- Revenue
- VIGL N/A
- OCCI N/A
- Revenue This Year
- VIGL N/A
- OCCI N/A
- Revenue Next Year
- VIGL N/A
- OCCI $10.19
- P/E Ratio
- VIGL N/A
- OCCI N/A
- Revenue Growth
- VIGL N/A
- OCCI N/A
- 52 Week Low
- VIGL $2.47
- OCCI $5.47
- 52 Week High
- VIGL $6.06
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- VIGL 32.87
- OCCI 44.14
- Support Level
- VIGL $2.89
- OCCI $7.02
- Resistance Level
- VIGL $3.26
- OCCI $7.42
- Average True Range (ATR)
- VIGL 0.22
- OCCI 0.12
- MACD
- VIGL -0.08
- OCCI 0.01
- Stochastic Oscillator
- VIGL 9.40
- OCCI 20.45
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.